Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Vildagliptin

First Posted Date: 2011-05-19

Last Posted Date: 2013-08-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01356381

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: QAX576
Drug: Infliximab

First Posted Date: 2011-05-18

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01355614

Locations: 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: LCZ696
Drug: Valsartan

First Posted Date: 2011-05-13

Last Posted Date: 2015-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01353508

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Phase 1

Active, not recruiting

Conditions: Pancreatic Cancer
BRAF Mutant Colorectal Cancer
Melanoma
Triple Negative Breast Cancer
Esophageal Squamous Cell Cancer
Lung Squamous Cell Cancer
Head and Neck Squamous Cell Cancer
Cervical Squamous Cell Cancer

Interventions: Drug: LGK974
Biological: PDR001

First Posted Date: 2011-05-10

Last Posted Date: 2024-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT01351103

Locations: 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute SC-7, Boston, Massachusetts, United States

and more 4 locations

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: AIN457
Biological: Placebo
Biological: Abatacept

First Posted Date: 2011-05-10

Last Posted Date: 2016-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 551

Registration Number: NCT01350804

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2

Completed

Conditions: Gorlin Syndrome
Nevoid Basal Cell Carcinoma Syndrome
Basal Cell Carcinoma

Interventions: Drug: Placebo
Drug: LDE225

First Posted Date: 2011-05-09

Last Posted Date: 2015-10-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01350115

Locations: 🇩🇪
Novartis Investigative Site, Kiel, Germany

Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

Phase 2

Terminated

Conditions: Fragile X Syndrome

Interventions: Drug: AFQ056

First Posted Date: 2011-05-05

Last Posted Date: 2016-05-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT01348087

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Iloperidone crystalline formulation
Drug: Iloperidone microparticle formulation
Drug: Oral iloperidone

First Posted Date: 2011-05-05

Last Posted Date: 2014-01-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT01348100

Locations: 🇺🇸
Novartis Investigative Site, Philadelphia, Pennsylvania, United States

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Uterine Leiomyoma
Metastatic Breast Cancer
Castration-resistant Prostate Cancer

Interventions: Drug: LFA102

First Posted Date: 2011-04-20

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT01338831

Locations: 🇺🇸
Massachusetts General Hospital Mass Gen 3, Boston, Massachusetts, United States
🇺🇸
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson, Philadelphia, Pennsylvania, United States
🇺🇸
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States

and more 3 locations

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit/Hyperactivity Disorder

Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release)

First Posted Date: 2011-04-20

Last Posted Date: 2014-11-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 299

Registration Number: NCT01338818

Locations: 🇸🇪
Novartis Investigative Site, Malmö, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy